SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Sleepman who wrote (14520)2/10/1998 10:04:00 AM
From: Henry Niman  Respond to of 32384
 
Dan, The Vitamin D compounds synergize with compounds that activate RXRs (rexinoids). LGND's consultants have also worked on the Vitamin D receptor for some time. LGND has over 200 pending patents. Some almost certainly impact Vitamin D3 analogs, Vitamin D receptors, and of course rexinoids and their receptors.